

| Response rate                                                                                                                                                                                                                                                | Description                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Complete metabolic response – CMR                                                                                                                                                                                                                            | Complete resolution of FDG activity within measurable lesions and all reliably assessable lesions to background levels. No new FDG-avid lesions in pattern typical of cancer*. Lymph nodes may remain metabolically active due to immune response (activated lymphocytes take up FDG).                                                             |
| Partial metabolic response – PMR                                                                                                                                                                                                                             | > 30 percent decrease in FDG activity measured as the summed SUVmax of measurable lesions (up to five lesions, max 2/organ). No new FDG-avid lesions in pattern typical of cancer*.                                                                                                                                                                |
| Minor metabolic response – MMR                                                                                                                                                                                                                               | 10-29 percent decrease in FDG summed SUVmax. No new FDG-avid lesions in pattern typical of cancer*.                                                                                                                                                                                                                                                |
| Stable metabolic disease – SMD                                                                                                                                                                                                                               | 0-9 percent decrease or up to < 30 percent increase in FDG summed SUVmax. No new FDG-avid lesions in pattern typical of cancer*.                                                                                                                                                                                                                   |
| Progressive metabolic disease – PMD                                                                                                                                                                                                                          | ≥ 30 percent increase in FDG summed SUVmax in pattern typical of tumor, or new clearly FDG-avid clinically significant lesions in pattern typical of cancer*. Increase in metabolic activity in lymph nodes should not result in PMD if no progression is detected elsewhere, since it might reflect immunological activation and not progression. |
| * “clinically significant lesions in pattern typical of cancer” defined as lesions associated with a CT abnormality most consistent with cancer (≥ 2 cm in diameter), and clearly not because of inflammation of infection or related to treatment response. |                                                                                                                                                                                                                                                                                                                                                    |

**Supplemental Table S1.** PET criteria used in TUNIMO.